Sumitomo Dainippon Pharma Co (DNPUF) Stock Statistics & Valuation Metrics

Sumitomo Dainippon Pharma Co has a market cap or net worth of $5.22B. The enterprise value is $791.57B.

Market Cap

$5.22B

Enterprise Value

$791.57B

Sumitomo Dainippon Pharma Co has 449,204,560 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding

449,204,560

Owned by Insiders

―

Owned by Institutions

6.16%

Sumitomo Dainippon Pharma Co’s return on equity (ROE) is 0.37 and return on invested capital (ROIC) is 8.81%.

Return on Equity (ROE)

0.37

Return on Assets (ROA)

0.13

Return on Invested Capital (ROIC)

8.81%

Return on Capital Employed (ROCE)

0.09

Revenue Per Employee

145.15M

Profits Per Employee

34.22M

Employee Count

3,123

Asset Turnover

0.56

Inventory Turnover

2.30

The current PE Ratio of Sumitomo Dainippon Pharma Co is 17.77. Sumitomo Dainippon Pharma Co’s PEG ratio is -0.24.

PE Ratio

17.77

PS Ratio

1.73

PB Ratio

1.97

Price to FCF

12.59

Price to Operating Cash Flow

12.06

PEG Ratio

-0.24

In the last 12 months, Sumitomo Dainippon Pharma Co had revenue of 453.29B and earned 106.86B in profits. Earnings per share was 268.99.

Revenue

453.29B

Gross Profit

256.89B

Operating Income

50.34B

Pretax Income

100.34B

Net Income

106.86B

EBITDA

131.32B

Earnings Per Share (EPS)

268.99

In the last 12 months, operating cash flow was 70.36B and capital expenditures -2.83B, giving a free cash flow of 67.54B billion.

Operating Cash Flow

70.36B

Free Cash Flow

67.54B

Free Cash Flow per Share

150.92

Sumitomo Dainippon Pharma Co pays an annual dividend of $0.05, resulting in a dividend yield of ―

Dividend Per Share

$0.05

Dividend Yield

―

Payout Ratio

N/A

Free Cash Flow Yield

7.86%

Earnings Yield

5.40%

Beta

0.45

52-Week Price Change

-1.88%

50-Day Moving Average

10.45

200-Day Moving Average

10.89

Relative Strength Index (RSI)

55.06

Average Volume (3m)

716

Sumitomo Dainippon Pharma Co upcoming earnings date is Jan 29, 2027, TBA (Not Confirmed).

Last Earnings Date

Oct 30, 2026

Next Earnings Date

Jan 29, 2027

Ex-Dividend Date

Mar 30, 2023

Sumitomo Dainippon Pharma Co as a current ratio of 1.03, with Debt / Equity ratio of 74.26%

Current Ratio

1.03

Quick Ratio

0.71

Debt to Market Cap

0.26

Net Debt to EBITDA

1.32

Interest Coverage Ratio

4.94

In the past 12 months, Sumitomo Dainippon Pharma Co has paid -6.52B in taxes.

Income Tax

-6.52B

Effective Tax Rate

-0.06

Sumitomo Dainippon Pharma Co EV to EBITDA ratio is 12.49, with an EV/FCF ratio of 13.63.

EV to Sales

1.87

EV to EBITDA

12.49

EV to Free Cash Flow

13.63

EV to Operating Cash Flow

13.09

Sumitomo Dainippon Pharma Co has $77.76B in cash and marketable securities with $139.69B in debt, giving a net cash position of -$61.93B billion.

Cash & Marketable Securities

$77.76B

Total Debt

$139.69B

Net Cash

-$61.93B

Net Cash Per Share

-$137.87

Tangible Book Value Per Share

$155.06

Gross margin is 53.27%, with operating margin of 9.64%, and net profit margin of 9.39%.

Gross Margin

53.27%

Operating Margin

9.64%

Pretax Margin

9.52%

Net Profit Margin

9.39%

EBITDA Margin

14.96%

EBIT Margin

10.89%

The average price target for Sumitomo Dainippon Pharma Co is $17.09, which is 11.43% higher than the current price. The consensus rating is Moderate Buy

Price Target

$17.09

Price Target Upside

45.78% Upside

Analyst Consensus

Moderate Buy

Analyst Count

1

Revenue Growth Forecast

4.77%

EPS Growth Forecast

-74.25%